Clinical Trials Browser

Phase 2 × OTHER × ON 01910 × Clear all

NCT05764395 2024-10-10

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Phase 2 Suspended

Melanoma

NCT02730884 2020-08-07

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Phase 2 Terminated

3 enrolled 6 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Splenomegaly, Primary Myelofibrosis